Venue: Boston

Location: Boston, United States

Event Date/Time: May 24, 2011 End Date/Time: May 26, 2011
Report as Spam


With many blockbusting antibody therapeutics hitting the market, and even more to follow over the next few years, it is crucial that supply keeps up with demand.
Several productivity bottlenecks need to be overcome in order to optimize the efficiency of antibody processing.
Following 2010’s successful meeting, Hanson Wade is again hosting the World Antibody Manufacturing & Development Summit to bring together thought leaders to drive antibody development forward.
• Get the latest market intelligence on the biosimilar landscape. Hear what next generation technologies can keep you ahead of the game
• Discover how to manage the lifecycle of a QbD product
• Be updated on the post-approval lifecycle management (PALM) plan that is being developed for antibody products undergoing licensing with QbD
• Refine your strategy for rapid transfer of protein therapeutics into existing manufacturing facilities
• See case studies of creative solutions to downstream capacity to maximise high cell culture productivity
• Learn about the best ways to approach the regulators and how QbD approaches can be included in regulatory submissions
• Acquire the key design tips for enhancing CMC probability of success
• Get advice on how to implement single-use processing across all unit operations
• Hear the latest case studies on antibody formulations, including stability comparability approaches, changing drug substance container, and the implications of moving to higher titers
• Get an insight into the latest techniques for high-throughput screening of chromatography resins
Designed entirely by industry, we’ve worked with thought leaders from Novartis, Merck & Co, Johnson & Johnson, Pfizer, MedImmune, Genentech, Abbott, Bayer, UCB, Amgen and more to produce a focussed program that tackles the challenges most relevant to you.
Your expert speaker panel includes:
• Victor Vinci, Director, Purification Development & Viral Safety, Eli Lilly
• Ron Taticek, Senior Director & Head, Genentech
• Michael Buckley, Vice President, Process Sciences, Takeda
• Kaia Agarwal, Vice President, Regulatory Affairs, Genzyme
• Mark Davis, Development Scientist, EMD Serono
• Paul Jorjorian, Engineer, Bristol-Myers Squibb
• Mayo Pujols, Director, MedImmune
• Stephen Lu, Senior Scientist, Abbott
• Brent Schreiber, Senior Engineer, Bristol-Myers Squibb
• Norbert Schuelke, Associate Director, Biologics Process Development, Millennium
• Mark Byers, Associate Director, Manufacturing Sciences, Biogen Idec
• Paul Hanson, Staff Engineer II, Millennium
• David Pollard, Associate Director, Bioprocess R&D, Merck & Co
• Hemant Joshi, Scientist IV, Process Development, Boehringer Ingelheim
• Jason Kantor, Research Analyst, RBC Capital Markets
• Kevin Maloney, Associate Director, protein Pharmaceutical Development, Biogen Idec
For more information about the agenda or what you can expect to learn please contact me at
Katie McQue, Program Director